Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -289.44% is 37% above its 5-year average of -456.70%, near the high end of its 5-year range (-1348.42%–-77.99%).
11.72% above its 12-month average of -327.87%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -355.90%.
NET PROFIT MARGIN
-289.44%
NET PROFIT MARGIN AVG TTM
-327.87%
NET PROFIT MARGIN AVG 3Y
-435.18%
NET PROFIT MARGIN AVG 5Y
-456.70%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+11.72%
CURRENT VS 3Y AVG
+33.49%
CURRENT VS 5Y AVG
+36.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 458 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
C4 Therapeutics, Inc.
Market Cap
$330.60M
Net Profit Margin
-289.44%
TTM Avg
-327.87%
3Y Avg
-435.18%
5Y Avg
-456.70%
Market Cap
$329.01M
Net Profit Margin
-214.74%
TTM Avg
-178.01%
3Y Avg
-157.31%
5Y Avg
-157.31%
Market Cap
$339.15M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$317.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-6520.67%
5Y Avg
-12425.66%
Market Cap
$345.48M
Net Profit Margin
-81.76%
TTM Avg
-64.66%
3Y Avg
-75.38%
5Y Avg
-73.80%
Market Cap
$348.59M
Net Profit Margin
0.00%
TTM Avg
-11651.99%
3Y Avg
-6142.69%
5Y Avg
-4693.07%
Market Cap
$348.85M
Net Profit Margin
8.59%
TTM Avg
7.90%
3Y Avg
10.47%
5Y Avg
19.48%
Market Cap
$361.64M
Net Profit Margin
-1091.82%
TTM Avg
-436.37%
3Y Avg
-220.06%
5Y Avg
-1750.93%
Market Cap
$363.54M
Net Profit Margin
69.34%
TTM Avg
-109.76%
3Y Avg
-150.31%
5Y Avg
-135.75%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | $330.60M | -289.44% | -327.87% | -435.18% | -456.70% |
| CapsoVision, Inc. (CV)vs › | $329.01M | -214.74% | -178.01% | -157.31% | -157.31% |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | 0.00% | 0.00% | 0.00% | 0.00% |
| Benitec Biopharma Inc. (BNTC)vs › | $317.09M | 0.00% | 0.00% | -6520.67% | -12425.66% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -81.76% | -64.66% | -75.38% | -73.80% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | 0.00% | -11651.99% | -6142.69% | -4693.07% |
| Embecta Corp. (EMBC)vs › | $348.85M | 8.59% | 7.90% | 10.47% | 19.48% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | -1091.82% | -436.37% | -220.06% | -1750.93% |
| Agenus Inc. (AGEN)vs › | $363.54M | 69.34% | -109.76% | -150.31% | -135.75% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -96.89% | -148.47% | -151.80% | -119.69% |
Operating Margin
-290.7%
Net Profit Margin
-289.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -355.90% |
| 2026-03-31 | -408.47% |
| 2025-12-31 | -185.97% |
| 2025-09-30 | -286.43% |
| 2025-06-30 | -402.60% |
| 2025-03-31 | -363.66% |
| 2024-12-31 | -667.82% |
| 2024-09-30 | -160.57% |
| 2024-06-30 | -147.56% |
| 2024-03-31 | -933.23% |
| 2023-12-31 | -1065.75% |
| 2023-09-30 | -244.19% |
| 2023-06-30 | -1348.42% |
| 2023-03-31 | -925.25% |
| 2022-12-31 | -1302.91% |
| 2022-09-30 | -473.17% |
| 2022-06-30 | -198.15% |
| 2022-03-31 | -413.12% |
| 2021-12-31 | -77.99% |
| 2021-09-30 | -290.39% |
| 2021-06-30 | -230.86% |
| 2021-03-31 | -282.40% |
| 2020-12-31 | -263.80% |
| 2020-09-30 | -258.49% |
| 2020-06-30 | -111.61% |
| 2020-03-31 | -174.77% |
| 2019-12-31 | -122.10% |
| 2019-09-30 | -188.18% |
| 2019-06-30 | -232.88% |
| 2019-03-31 | -232.88% |
